MedAdvisor Solutions Poised for Record FY24 Performance

Key Highlights

• Strong Market Momentum: Growth in both the United States and Australian business units continued into Q4 FY24.
• Historic Profit Achievement: Expected to reach inaugural full-year EBITDA and NPAT profit.
• FY24 Financial Guidance:
  • Revenue: AU$120 million - AU$123 million, an increase of AU$22 million - AU$25 million from FY23
  • EBITDA: AU$6.8 million - AU$7.6 million, up AU$9.8 million -AU$10.6 million from FY23
  • NPAT: AU$0.5 million - AU$0.8 million, up AU$11.8 million - AU$12.1 million from FY23
• Growth Drivers: Significant contributions from THRiV in the US and increased transaction fees in Australia.
• Positive FY25 Outlook: Continued growth anticipated due to the adoption of omni-channel solutions and new service rollouts.

MedAdvisor Solutions (ASX: MDR) is set to achieve record financial performance in FY24, driven by strong growth in key markets and innovative solutions.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com